NASDAQ:CLRB Cellectar Biosciences (CLRB) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free CLRB Stock Alerts $3.03 +0.01 (+0.33%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.98▼$3.1250-Day Range$3.02▼$4.2452-Week Range$1.33▼$4.45Volume686,677 shsAverage Volume891,528 shsMarket Capitalization$97.75 millionP/E RatioN/ADividend YieldN/APrice Target$20.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cellectar Biosciences alerts: Email Address Cellectar Biosciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside560.1% Upside$20.00 Price TargetShort InterestHealthy7.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.85) to ($0.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.22 out of 5 starsMedical Sector520th out of 914 stocksPharmaceutical Preparations Industry227th out of 418 stocks 3.5 Analyst's Opinion Consensus RatingCellectar Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCellectar Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.49% of the float of Cellectar Biosciences has been sold short.Short Interest Ratio / Days to CoverCellectar Biosciences has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cellectar Biosciences has recently decreased by 13.44%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectar Biosciences does not currently pay a dividend.Dividend GrowthCellectar Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLRB. Previous Next 2.5 News and Social Media Coverage News SentimentCellectar Biosciences has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cellectar Biosciences this week, compared to 1 article on an average week.Search Interest5 people have searched for CLRB on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cellectar Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -90% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectar Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Cellectar Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Cellectar Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cellectar Biosciences are expected to grow in the coming year, from ($1.85) to ($0.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectar Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectar Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Cellectar Biosciences Stock (NASDAQ:CLRB)Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Read More CLRB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLRB Stock News HeadlinesApril 19, 2024 | seekingalpha.comCLRB Cellectar Biosciences, Inc.March 29, 2024 | markets.businessinsider.comBuy Rating on Cellectar Biosciences Backed by Promising Drug Candidate and Solid FinancialsApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 29, 2024 | nz.finance.yahoo.comJeremy Renner Sweetly Hugs Daughter Ava in Rare Photo as He Celebrates His 'Number One' on Her 11th BirthdayMarch 29, 2024 | finance.yahoo.comCellectar Biosciences, Inc. (NASDAQ:CLRB): When Will It Breakeven?March 28, 2024 | finance.yahoo.comQ4 2023 Cellectar Biosciences Inc Earnings CallMarch 27, 2024 | investorplace.comCLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023March 27, 2024 | msn.comCellectar Biosciences FY 2023 Earnings PreviewApril 27, 2024 | Behind the Markets (Ad)Better than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 27, 2024 | benzinga.comEarnings Preview For Cellectar BiosciencesMarch 27, 2024 | globenewswire.comCellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate UpdateMarch 20, 2024 | globenewswire.comCellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024March 14, 2024 | globenewswire.comCellectar Biosciences to Present at the 36th Annual Roth ConferenceMarch 4, 2024 | globenewswire.comCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck CancerFebruary 22, 2024 | benzinga.comCellectar Biosciences Stock (NASDAQ:CLRB), Short Interest ReportFebruary 15, 2024 | money.usnews.comCellectar Biosciences IncFebruary 12, 2024 | seekingalpha.comCellectar Biosciences: A Shoestring Opportunity You're About To MissFebruary 7, 2024 | finance.yahoo.comCellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 25, 2024 | finance.yahoo.comCellectar Biosciences Announces Tranche A Warrants Fully Exercised, Providing Proceeds of $44.1 MillionJanuary 23, 2024 | investing.comCellectar Biosciences Inc (CLRB)January 22, 2024 | msn.comCellectar stock climbs 8% on results for CNS malignancy therapyJanuary 22, 2024 | finance.yahoo.comCellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia PatientJanuary 16, 2024 | finance.yahoo.comCellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy (TAT) for Solid Tumors and Releases Promising Preclinical DataJanuary 12, 2024 | finance.yahoo.comCellectar Biosciences to Host Conference Call with Texas Oncology Hematologist M. Yair Levy, M.D. on January 19, 2024 to Discuss Iopofosine I 131 Pivotal Topline ResultsJanuary 8, 2024 | marketwatch.comCellectar Biosciences Shares Hit 52-Week High After Positive Iopofosine I ResultsJanuary 8, 2024 | msn.comWhy Is Cancer-Focused Cellectar Biosciences Stock Trading Higher Today?January 8, 2024 | marketwatch.comCellectar Biosciences' Iopofosine I Meets Primary Endpoint in Rare Blood Cancer StudySee More Headlines Receive CLRB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2024Today4/27/2024Next Earnings (Estimated)5/02/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLRB CUSIPN/A CIK1279704 Webwww.cellectar.com Phone(608) 441-8120Fax608-441-8121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$20.00 High Stock Price Target$28.00 Low Stock Price Target$12.00 Potential Upside/Downside+560.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-3,821.29% Return on Assets-280.23% Debt Debt-to-Equity RatioN/A Current Ratio0.81 Quick Ratio0.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.36) per share Price / Book-8.42Miscellaneous Outstanding Shares32,260,000Free Float30,777,000Market Cap$97.75 million OptionableOptionable Beta0.92 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. James V. Caruso (Age 65)President, CEO & Director Comp: $846.48kMr. Chad J. Kolean CPA (Age 60)VP, CFO & Secretary Comp: $453.22kMr. Jarrod Longcor (Age 51)Chief Operating Officer Comp: $625.32kMr. Darrell Shane Lea (Age 51)Chief Commercial Officer Dr. Andrei Shustov M.D. (Age 53)Senior Vice President of Medical Key CompetitorsBarinthus BiotherapeuticsNASDAQ:BRNSVaccitechNASDAQ:VACCClearside BiomedicalNASDAQ:CLSDAnixa BiosciencesNASDAQ:ANIXIO BiotechNASDAQ:IOBTView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Sold 1,384,180 shares on 4/25/2024Ownership: 1.926%ADAR1 Capital Management LLCBought 1,378,082 shares on 2/14/2024Ownership: 11.213%AIGH Capital Management LLCBought 1,237,709 shares on 2/12/2024Ownership: 15.584%Worth Venture Partners LLCBought 414,786 shares on 2/9/2024Ownership: 5.646%View All Institutional Transactions CLRB Stock Analysis - Frequently Asked Questions Should I buy or sell Cellectar Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLRB shares. View CLRB analyst ratings or view top-rated stocks. What is Cellectar Biosciences' stock price target for 2024? 2 brokerages have issued twelve-month target prices for Cellectar Biosciences' shares. Their CLRB share price targets range from $12.00 to $28.00. On average, they expect the company's stock price to reach $20.00 in the next year. This suggests a possible upside of 560.1% from the stock's current price. View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts. How have CLRB shares performed in 2024? Cellectar Biosciences' stock was trading at $2.77 at the start of the year. Since then, CLRB stock has increased by 9.4% and is now trading at $3.03. View the best growth stocks for 2024 here. Are investors shorting Cellectar Biosciences? Cellectar Biosciences saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 2,190,000 shares, a decrease of 13.4% from the March 31st total of 2,530,000 shares. Based on an average daily trading volume, of 1,110,000 shares, the days-to-cover ratio is currently 2.0 days. Approximately 7.5% of the company's shares are short sold. View Cellectar Biosciences' Short Interest. When is Cellectar Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our CLRB earnings forecast. How were Cellectar Biosciences' earnings last quarter? Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings results on Wednesday, March, 27th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. When did Cellectar Biosciences' stock split? Cellectar Biosciences shares reverse split before market open on Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Cellectar Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM). Who are Cellectar Biosciences' major shareholders? Cellectar Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Rosalind Advisors Inc. (1.93%). View institutional ownership trends. How do I buy shares of Cellectar Biosciences? Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLRB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe World's First "$20 Trillion Drug?"Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectar Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
